Emzor Pharmaceutical Industries Limited, a top industry player, has restated its commitment to supporting efforts curb the high prevalence of malaria in Nigeria and across Sub-Saharan Africa. This coincides with the world’s commemoration of World Malaria Day 2025, themed “Malaria Ends with Us: Reinvest, Reimagine, Reignite.”
According to Kunle Faloye, head of Marketing and Strategy at Emzor Pharmaceutical Industries Limited, the company has a long-established history of leadership in malaria prevention and treatment. He highlighted the company’s commitment to producing high-quality antimalarial drugs that are both readily available and affordable for millions of people throughout Africa.“Our dedication is reflected in our investment in research, development, and wide-reaching distribution networks, which have played a crucial role in reducing the malaria burden,” he said.
To mark World Malaria Day 2025, Emzor organised a series of impactful community outreach activities, including a health walk, free medical screenings, and the distribution of antimalarial drugs to vulnerable populations. Malaria continues to be a leading cause of death among pregnant women and children under five in Africa. Emzor’s initiatives in malaria control include the production of essential antimalarial drugs aimed at reducing maternal and infant mortality rates.
Emzor currently produces over 20 antimalarial medicines, including Maldox Sulfadoxine/Pyrimethamine), Lokmal (Artemether/Lumefantrine), Piramal TS (Dihydroartemisinin/Piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, in different dosage forms. Further underscoring this commitment is Emzor’s multimillion-dollar investment in the manufacture of Active Pharmaceutical Ingredients (API), in a modern manufacturing Pharmaceutical Campus located in Sagamu, Ogun State.
The plant will initially focus on the production of antimalarial APIs (namely Arthemeter, Lumefantrine, Sulfadoxine and Pyrimethamine). The selected APIs provide the WHO-recommended treatment of malaria for adults and children, as well as the chemo-preventive combination therapies for malaria in both pregnant women and children under five. This strategic investment boosts Nigeria’s capacity to locally produce a broad range of antimalarial drugs, thereby improving access to high-quality treatments across sub-Saharan Africa. The project further underscores Emzor’s commitment to strengthening the pharmaceutical sector in the region.The project’s positive impact will reduce Nigeria’s dependence on imports from Asia, support GDP growth and reduce the demand for foreign exchange, and reduce the cost of production and access to these life-saving medicines by the people who need them most.
Emeka Okoli, chairman of the Board of Directors of Emzor Pharmaceutical Industries Limited, said, “With approximately 95 per cent of all malaria cases and 96 per cent of the deaths occurring on the continent, this is predominantly an African problem and hence, the solutions should also largely come from the continent. At Emzor, we are playing our part and pioneering the API project on the continent definitely fits into this.
Emzor also works in partnership with local governments, NGOs, and communities to implement grassroots outreach programmes focused on education, prevention, diagnosis, and treatment. The company continues to provide subsidised and free medications to pregnant women and children, the groups most vulnerable to malaria.
“As we mark this important day, Emzor remains steadfast in our resolve to contribute to global efforts toward malaria eradication. We will continue to innovate, collaborate, and invest in sustainable healthcare solutions that enhance lives across Nigeria and the continent,” added Faloye.
